Surface Ophthalmics, Inc.
Pharmaceutical therapeutics for ocular diseases
- Sector
- Biotech
- Headquarters
- PLEASANTON, CA
- Founded
- 2017
- Latest Form D
- $5.8M, Jun 2021
- Total capital
- $20.8M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $20.8M
- 2 Form D · last Jun 2021
- 65 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 4
- 13 pending · first 2023
- Rank in peer group#293 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 2nd filing$5.8M
- Private capital raisedForm D · SEC · 1st filing$15M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#293 · top 20%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Richard LindstromResearcherDirectorLinked by 2 patents
- Kamran HosseiniResearcherExecutive Officer, DirectorLinked by 1 patent
- Adrienne Andy GravesDirectorNamed in SEC Form D filings
- J. Andy CorleyDirectorNamed in SEC Form D filings
- Mark BaumDirectorNamed in SEC Form D filings
- Perry Andy SternbergExecutive Officer, DirectorNamed in SEC Form D filings
Show all 7 people
- Shelley Andy ThunenDirectorNamed in SEC Form D filings
What it has protected
USPTO · 4 granted of 17- PendingEye Drop Formulations Containing Chondroitin Sulfate For Relieving Ocular Pain Or DiscomfortUSPTOApplication 19329207
- GrantedUse Of Chondroitin Sulfate For Relieving Ocular PainUSPTOUS 12,440,510
- GrantedUse Of Chondroitin Sulfate For Relieving Ocular PainUSPTOUS 12,310,981
Show all 17 patent records
- Eye Drop Formulations Containing Chondroitin Sulfate For Relieving Ocular Pain Or DiscomfortJan 8, 2026 · Application 19329207Pending
- Use Of Chondroitin Sulfate For Relieving Ocular PainOct 14, 2025 · US 12,440,510Granted
- Use Of Chondroitin Sulfate For Relieving Ocular PainMay 27, 2025 · US 12,310,981Granted
- Ophthalmic Pharmaceutical Compositions And Methods For Treating Ocular Surface DiseaseAug 27, 2024 · US 12,070,442Granted
- Ophthalmic Pharmaceutical Compositions And Methods For Treating Ocular Surface DiseaseSep 26, 2023 · US 11,766,421Granted
- Pharmaceutical Kits And Their Use For Treating Dry Eye DiseaseSep 7, 2023 · Application 18131841Pending
- Pharmaceutical Compositions Of Mycophenolic Acid And/or Betamethasone For The Treatment Of Ocular DisordersMay 25, 2023 · Application 18100505Pending
- Ophthalmic Pharmaceutical Compositions And Methods For Treating Ocular Surface DiseaseMay 12, 2022 · Application 17582627Pending
- Use Of Chondroitin Sulfate For Relieving Ocular PainApplication 63186747Pending
- Ophthalmic Pharmaceutical Compositions And Methods For Treating Ocular Surface DiseaseApplication PCTUS2019064371Pending
- Eye Drop Formulations Containing Chondroitin Sulfate For Relieving Ocular Pain Or DiscomfortApplication PCTUS2025024021Pending
- Pharmaceutical Compositions Of Mycophenolic Acid And/or Betamethasone For The Treatment Of Ocular DisordersApplication PCTUS2023011351Pending
- Pharmaceutical Compositions Of Mycophenolic Acid And/or Betamethasone Sodium Phosphate For The Treatment Of Ocular DisordersApplication 63415419Pending
- Pharmaceutical Compositions Of Mycophenolic Acid And/or Betamethasone Sodium Phosphate For The Treatment Of Ocular DisordersApplication 63402704Pending
- Use Of Chondroitin Sulfate For Relieving Ocular PainApplication PCTUS2022027177Pending
- Topical Application Of Mycophenolic Acid And Betamethasone Sodium Phosphate For The Treatment Of Ocular Surface DiseaseApplication 63317770Pending
- Pharmaceutical Kits And Their Use For Treating Dry Eye DiseaseApplication PCTUS2021053552Pending
Related companies, and why
- Pandion TherapeuticsSimilar federal contract value in Biotech · null in contracts
- BRITEBIO, INC.Similar federal contract value in Biotech · null in contracts
- LumaCyte, Inc.Similar federal contract value in Biotech · null in contracts
- MethylGene Inc.Similar federal contract value in Biotech · null in contracts
- OtonomySimilar federal contract value in Biotech · null in contracts
- Endlyz Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .